Mitsubishi Chemical Corporation

Basis: Figures for FY2021–FY2023 are as originally reported (Pharma included). FY2024 is shown on the restated continuing-operations basis where stated (Pharma = discontinued) and FY2025 on the current basis. Net income attributable to owners is unaffected by the reclassification. Sources: MCG Yuho FY2021–FY2025 via EDINET; MCG Kessan Tanshin FY2025 (13 May 2026).

Income statement: notes and sources

Notes: FY2024 gross profit and SG&A are on the original (Pharma-inclusive) basis and are therefore not directly comparable with FY2025. FY2024 income before taxes is derived from the FY2025 YoY decline of JPY 98.5bn. Core operating income for FY2021–FY2023 is not shown because consistently restated figures were not captured; FY2024 and FY2025 are per the FY2025 earnings call. FY2025 operating income of JPY 30.1bn reflects c. JPY 195bn of net non-recurring losses (coke/carbon exit c. JPY 85bn, UK Soarnol impairment, "Next Stage" special retirement programme of JPY 31.9bn at MCC, other restructuring).

Margins and growth

FY2024 operating and net margins are computed on restated continuing revenue (JPY 3,947.6bn). Revenue CAGR FY2021–FY2025 (as reported): -1.8% p.a.; the FY2022 peak (JPY 4,634.5bn) reflected naphtha-driven price inflation and the weak yen, and the subsequent decline reflects commodity deflation plus the Pharma deconsolidation. EBITDA is not reported by MCG; an EDINET-derived EV/EBITDA of 8.8x on EV of JPY 2.66tn implies FY2025 EBITDA of roughly JPY 300bn (derived, not company-reported).

Balance sheet

Prior-year balance sheets: equity ratio was 29.5% at 31 March 2025 (EDINET); equity attributable to owners was JPY 1,458.1bn at 31 March 2022 (Yuho FY2021). Full multi-year balance sheet series not captured in this cycle and therefore not tabulated. Discrepancy: EDINET DB reports a "net cash" figure of JPY -2.02tn, which likely includes lease liabilities and/or other debt-like items; the JPY ~1.36tn shown above is simple interest-bearing debt less cash. Working capital: current ratio 150% (EDINET); working capital/total assets 0.118 ⇒ c. JPY 690bn (derived).

Cash flow

FY2025 investing cash flow was positive because Pharma sale proceeds (c. JPY 510bn) exceeded capex and acquisitions (Coregas JPY 71.5bn; ETH Spain JPY 22.4bn). Buybacks: none material verified for FY2025; treasury stock disposals related to stock compensation (BIP trust) were executed in 2026.

Trend commentary

The five-year record shows a company whose reported profitability has deteriorated almost every year since the FY2021 recovery peak (net income JPY 177.2bn, ROE 13.2%) to FY2025 (JPY 11.8bn, ROE 0.7%), while underlying core operating income has been far more stable (JPY 228.8bn → 225.0bn on a continuing basis). The gap is entirely non-recurring: portfolio clean-up costs (coke, carbon materials, Soarnol UK, emulsion, triacetate, J-Film), headcount reduction, and impairments. Cash generation remained robust (OCF JPY 436bn even in the trough year), and the Pharma sale de-risked the balance sheet. The inflection signal is Q1 FY2026: core OI of JPY 114.1bn (half of the entire FY2025 total in one quarter), helped partly by non-structural tailwinds (naphtha-linked inventory valuation gains and pre-buying amid Middle East supply fears).

FY2025 quarterly progression

Q2–Q4 FY2025 revenue derived from cumulative disclosures (H1 JPY 1,799.1bn; 9M JPY 2,737.3bn; FY JPY 3,704.0bn).

Management guidance (FY2026, year to March 2027)

H1 FY2026 guidance (raised 31 July 2026): revenue JPY 2,043bn, core OI JPY 194bn, NI JPY 86bn. Full-year guidance was left unchanged, implying a cautious H2 (core OI ~JPY 111bn) amid feedstock and geopolitical uncertainty.

Bull case

1. Specialty compounding is real: Specialty core OI went from JPY 23.9bn (FY2024) to 32.3bn (FY2025) and 38.3bn in a single quarter (Q1 FY2026), supporting management's JPY 144bn FY2029 ambition.

2. Clean-up largely done: With Pharma sold, coke exited and emulsions, J-Film, triacetate and logistics divested, FY2026 operating income should converge toward core OI (guided JPY 300bn vs. 305bn), driving ROE back to the mid-to-high single digits.

3. Valuation optionality: At ~0.7–0.9x book with a stable gases annuity, consolidation (ethylene JV, petrochemical spin-off) could unlock value and lower capital intensity.

Bear case

1. Q1 quality: Part of Q1's doubling came from naphtha-linked inventory gains and temporary customer stockpiling, which can reverse in H2 — management itself held full-year guidance flat.

2. Commodity structural pressure: Chinese MMA and petrochemical overcapacity may cap the MMA recovery; Basic Materials remained loss-making at core level in FY2025.

3. Credibility and leverage: Six consecutive years of material non-recurring charges, D/E of ~1.07x and goodwill at ~51% of net assets leave limited buffer if another down-cycle arrives before restructuring completes.

Catalysts and monitorables (next 12 months)

Analyst verdict

Mitsubishi Chemical Corporation sits at the most consequential point in its modern history. The group has done the hard, unglamorous work that its predecessors deferred: selling the pharmaceutical business it bought out only five years earlier, exiting the coke operations that date back to its 1934 origins, agreeing to close a shared ethylene cracker, and preparing its basic petrochemicals for separation. The accounting cost of that clean-up was severe — FY2025 net income of just JPY 11.8bn and ROE of 0.7% — but the underlying engine held steady, with core operating income of JPY 225bn and operating cash flow above JPY 430bn.

The investment debate therefore turns on whether core earnings can now flow through to the bottom line and whether the chemical segments can carry more of the load currently borne by industrial gases. The early evidence is encouraging: Specialty Materials is outrunning plan, MMA has returned to profit, and Q1 FY2026 core operating income doubled. Yet that quarter was flattered by inventory gains and precautionary customer buying linked to Middle East disruption, and management's decision to hold full-year guidance unchanged is a sober signal that H2 will be harder.

On balance, the risk-reward has improved materially relative to a year ago. Valuation below book, a maintained JPY 32 dividend, an A+ rating and a visible restructuring roadmap provide downside support, while specialty growth and domestic industry consolidation offer upside. The decisive tests over the next twelve months are (1) delivering FY2026 operating income near the JPY 300bn guide without fresh large charges, (2) proving that Specialty Materials can sustain a quarterly run-rate well above JPY 30bn, and (3) executing the ethylene JV and spin-off on schedule. Success on all three would mark a genuine re-rating from restructuring story to specialty compounder; failure on any would revive doubts that have accumulated across a decade of reorganisations.